MAPT and Alzheimer disease: In this context, determination of different forms of tau protein in brain, CSF (43) and also in blood (44) and peripheral cells (15) has been postulated as a powerful tool for detection and monitoring of the disease in different stages and there is clear evidence of a profile of tau and other biomarkers modifications during AD progression (45, 46).